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Introduction
Acute urinary retention (AUR) is a common
complication of a neoplastic prostate. Transurethral
resection of the prostate (TURP) may offer immediate
relief of the obstruction in patients with benign
prostatic hyperplasia (BPH).1 In contrast, palliative
TURP (the so-called “channel” TURP), by definition,
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Background: Few studies have focused on clinical findings in prostate cancer patients receiving transurethral
resection of the prostate (TURP) for acute urinary retention (AUR). We compared the clinical findings (preoperative
characteristics, operative morbidities, and pathology results) of patients with diagnosed prostate cancer undergoing
palliative TURP for AUR with those of patients undergoing TURP for AUR who were diagnosed with prostate cancer
postoperatively.
Methods: The charts of 25 patients with prostate cancer undergoing TURP for AUR between 1986 and 2003 were
retrospectively reviewed. Fourteen patients underwent palliative TURP (group A) and the other 11 patients with newly
diagnosed prostate cancer received TURP (group B). The data, including preoperative characteristics, operative
morbidities, and pathology results were analyzed.
Results: There were no significant differences between the 2 groups in parameters such as age at diagnosis and
operation, operative time, hospitalization, and catheter duration. However, the Gleason score was higher in group
A (7.6 ( 1.7) than in group B (5.4 ( 1.8) (p < 0.005). The mean resected weight was lower in group A (19.9 g)
than in group B (39.5 g). Group A was more likely to receive recatheterization (33.3% vs 0%, p = 0.058) and repeat
operation (28.6%), although the difference was not statistically significant. There were no complications such as
transurethral resection syndrome or perioperative death in either group.
Conclusion: TURP can be performed safely for relief of AUR in patients with prostate cancer, no matter if the cancer
was diagnosed before or after surgery. The higher Gleason score and more advanced cancer stage, as found in
group A, may correlate to high recatheterization and reoperation rates due to preexisting tumor progression. [J Chin
Med Assoc 2006;69(1):21–25]
Key Words: prostate cancer, transurethral prostate resection, urinary retention
is a transurethral resection of prostate tissue in a
patient with metastatic or locally advanced and/or
previously treated prostate cancer to alleviate
obstructive voiding symptoms (e.g. AUR), and,
therefore, resection to the depth of the prostatic
capsule is not attempted.2
Prostate cancer is a relatively common cancer for
older men, and they may develop AUR as the disease
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progresses. Crain et al3 have stated that, in comparison
with the standard TURP for BPH, palliative TURP
can also be performed safely in patients with advanced
prostate cancer with significant improvement in
urinary symptoms. In a series of 85 patients
undergoing TURP for symptomatic BPH, Ornstein
et al4 found that prostate cancer may be detected in
a significant proportion (> 15%) of these patients
despite prior screening with the serum prostate specific
antigen (PSA) test, digital rectal examination (DRE),
and 1 or more systematic needle biopsies of the
prostate.  In our study, patients undergoing TURP
for AUR were divided into 2 groups to compare their
preoperative characteristics, operative morbidities,
and pathology results. Group A consisted of patients
with diagnosed prostate cancer undergoing palliative
TURP for AUR. Group B included patients
undergoing TURP for AUR who had cancer
diagnosed postoperatively in the resected prostate
specimen. We wanted to see if cancer diagnosed
before or after the operation would influence the
outcome of TURP.
Methods
We performed a retrospective review of 18 palliative
TURP procedures in 14 patients with known prostate
cancer (group A) and 11 TURP procedures in patients
who had newly diagnosed prostate cancer by TURP
for BPH (group B) owing to AUR. The procedures
were performed at the Division of Urology of Taipei
Veterans General Hospital between 1986 and 2003.
Inpatient and outpatient charts, clinical records,
operative reports, and discharge summaries were
reviewed. For each patient, several parameters were
reviewed including preoperative characteristics,
operative morbidities, and pathology results. The mean
follow-up period was 16.6 months (range 0.5–108).
Surgery was performed with the patient under
spinal anesthesia. All operative procedures were
performed by a chief resident or staff urologist. In all
cases, prophylactic antibiotics (gentamycin and/or
cephalosporin) were administered. All resected tissues
were weighed and submitted for pathologic review.
The Gleason score (GS) was made according to the
Gleason grading system, which is based on the degree
of loss of the normal glandular tissue architecture, as
originally described and developed by Gleason in
1974.5,6 The stage was determined based on the
TNM staging system (American Joint Committee on
Cancer, 2002).7 Urethral catheters were placed
postoperatively.
The following parameters were compared between
the 2 groups: mean age at diagnosis, age at (palliative)
TURP, operative time, resected tissue weight,
pathology results, postoperative morbidities,
complications, length of hospital stay, and catheter
duration. The Mann-Whitney test and Fisher’s exact
test were used to determine statistical significance,
which was set at p < 0.05.
Results
The data of 14 patients with known prostate cancer
undergoing 18 palliative TURPs and 11 patients
with BPH and undetected prostate cancer undergoing
11 TURPs were collected and analyzed. The
preoperative, operative, and postoperative parameters
in both groups of patients are shown in Table 1.
Results showed no significant differences in age at
cancer diagnosis and surgery. Prior to palliative TURP
in 14 patients, 6 received hormonal therapy, and 1
was treated with radiation therapy. The mean operative
time, hospital stay, and catheter duration were not
significantly different. Complications such as
transurethral resection syndrome and perioperative
mortality were not noted.
Postoperative morbidities included: failure of
initial voiding in 3 of 18 procedures in group A;
urge incontinence in 2 of 18 in group A versus 2 of
11 in group B; recatheterization and repeat operation
were more frequent in group A compared with
group B, although the difference was not statistically
significant.
In group A, GS was low grade in only 1 procedure,
moderate grade in 8 procedures, and high grade in 7
procedures. In 2 procedures, only BPH was found. On
the other hand, in group B, GS was low grade in 2
patients and moderate grade in 8, and no high grade
was found. The mean GS was significantly higher in
group A than in group B (7.6 ( 1.7 vs 5.4 ( 1.8,
p < 0.005) (Figure 1).
The TNM cancer staging system was used in
prostate cancer patients. Of the 18 palliative TURP
procedures, 1 each had T2aN0M0, T2bN0M0,
T3aN0M0, T3cN0M0, T1cN0M1b, T2aN0M1b,
T3cN0M1b, T2bN0M1c, and T2cN1M1c; 4 had
T2bN0M1b; 3 had T2cN0M1b; and 2 had
T2bN1M1b. Among 11 prostate cancers detected at
TURP, 3 had T1aN0M0; 2 each had T1bN0M0,
T2aN0M0, and T2cN0M0; and 1 each had T1cN0M0
and T1cN0M1b. Thus, advanced cancer staging
(N1-3 and/or M1a-1c) was found more frequently in
group A (77.8%) than in group B (9.1%).
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Discussion
Prostate cancer is one of the most common epithelial
tumors in older men. Bladder outlet obstruction, for
example AUR, caused by the enlarged neoplastic
prostate is very common. Endocrine therapy can be
the first line of treatment for obstructive voiding
Table 1. Preoperative, operative, and postoperative parameters in the palliative TURP and TURP groups
Group A Group B
Palliative TURP TURP
(14 patients) (11 patients)
Mean ( SD Range Mean (  SD Range
p
Preoperative characteristic
Age at diagnosis, yr 74.50 ( 5.45 65–83 73.64 ( 8.23 65–94 0.404*
Age at operation, yr 75.83 ( 4.62 66–84 73.64 ( 8.23 65–94 0.149*
Operative parameter
Operative time, min 62.94 ( 32.70 20–120 70.91 ( 43.35 30–185 0.758*
Resected weight, g 19.94 ( 14.88 4–71 39.45 ( 34.68 10–120 0.079*
Catheter time, d 2.69 ( 1.01 2–5 2.25 ( 0.46 2–3 0.316*
Hospital stay, d 12.00 ( 5.67 4–23 8.64 ( 4.72 4–18 0.104*
Postoperative morbidity
Failed initial voiding‡ 16.7% 0 0.268†
Urge incontinence‡ 11.1% 18.1% 0.861†
Recatheterization‡ 33.3% 0 0.058†
Reoperation§ 28.6% 0 0.105†
Complication
Transurethral resection syndrome 0 0
Perioperative death 0 0
*Compared with Mann-Whitney test. †Compared with Fisher’s exact test. ‡% of procedures. §% of patients. TURP = transurethral resection of prostate.
Figure 1. Percentage of patients with low, moderate, and high
Gleason scores: palliative TURP (group A) and TURP (group B).
symptoms, but it may take a period of time to achieve
its effect. A success rate of 69% was reported in 35 men
with prostatic carcinoma treated with orchiectomy;
however, 29% of patients required TURP within 90
days after orchiectomy.8 In our study, combined
palliative TURP and bilateral orchiectomy was
performed in 10 patients, and repeat palliative TURPs
to relieve urinary retention in 3 (30%). Although
dissemination of locally advanced prostate cancer
may be caused by TURP,9–12 it also may provide
immediate relief of the obstruction and may be safely
employed for patients with persistent obstructive
symptoms.2,3
Complications and morbidities related to TURP
include blood loss, fluid balance disturbances, excessive
fluid absorption, incontinence, and erectile dysfunction.1
Few studies focused on the operative morbidities of
TURP in men with prostate cancer. Two series of men
with prostate cancer undergoing palliative TURP have
been reported by Mazur and Thompson2 and Crain et
al.3 Both concluded that palliative TURP can be
performed safely in patients with advanced prostate
cancer. In comparison with our data, their studies
found similar mean age at operation and reoperation
rate (Table 2). Regarding postoperative morbidities,
%
 o
f 
pa
tie
nt
s
0
10
20
30
40
50
60
70
80
90
Low (2–4) Moderate (5–7) High (8–10)
Gleason score
Palliative TURP
TURP
C.C. Chang, et al
J Chin Med Assoc • January 2006 • Vol 69 • No 124
Crain et al3 reported a somewhat lower recatheterization
rate than we did. In our series, however, the mean
hospital stay of 12 days was significantly different from
the 1.8 days reported by Crain et al. Several factors
might contribute to this discrepancy, including a
combination of other surgical interventions such as
orchiectomy and larger resection leading to an increased
likelihood of hemorrhage. In our study, patients were
not discharged until successful voiding was achieved
after catheter removal, rather than discharge with
catheter. This may explain the higher recatheterization
rate and longer hospital stay in our study as compared
with that by Crain et al.
Our study showed no significant differences
between the 2 groups in age at diagnosis and surgery,
operative time, length of hospital stay, and catheter
duration. The mean weight of tissue resected was
19.9 g in group A versus 39.5 g in group B. The
difference might be because palliative TURP was
limited to creating a channel for urinary flow, unlike
the standard TURP for BPH that intended to resect to
the depth of the prostatic capsule.3 Lower weight
might also be correlated to a higher recatheterization
rate. The majority of patients undergoing palliative
TURP (group A) were also found to have cancers of a
higher grade and more advanced stage. Again, bladder
outlet obstruction caused by local tumor progression
and recurrence of preexisting cancer was coincident
with a higher reoperation rate. Although the patients
in group B had prostate cancers detected by TURP for
BPH, they were of moderate grade and only 1 was at
T1cN0M1b stage. A significant number of patients in
group B were found to have stages T1a–1cN0M0
(54.5%); however, less aggressive prostate cancer may
have a tendency to develop centrally in the transition
zone where it is more likely to cause obstructive
symptoms.13 In addition, 2 patients in group B
underwent transrectal ultrasonography-guided
biopsies to rule out prostate cancer before TURP, yet
the pathology results revealed BPH. It suggests that
men who have prostate cancer with obstructive
symptoms may have coexistent BPH and a cancer
Table 2. Studies evaluating outcomes of palliative TURP
Study Mazur and Thompson2, 1991 Crain et al,3 2004 Present study, 2005
Age at operation, yr 74 74.2 75.8
Failed initial voiding, % — 42 16.7
Recatheterization, % — 8.3 33.3
Reoperation, % 22 29 29
Hospitalization, d — 1.8 12
TURP = transurethral resection of prostate.
diagnosis may be missed or delayed despite thorough
preoperative evaluation with serum PSA, DRE, and
systemic needle biopsies of the prostate.4
In conclusion, TURP can be performed safely with
an acceptable morbidity rate for relief of AUR in
patients with prostate cancer, no matter if the cancer
was diagnosed before or after surgery. Higher GS and
more advanced cancer stage were found in the
palliative TURP group (group A). These findings
may correlate to the high recatheterization and
reoperation rate due to preexisting tumor progression
in patients of group A.
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